about
Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials.TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myelomaEarly versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trialsSynergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2.Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trialsCarfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.Pterostilbene induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma cells.Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo.The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.Antitumor effect of dobutamine on multiple myeloma via mitogen-activated protein kinase pathway in vitro.Antitumor activity of fucoidan against diffuse large B cell lymphoma in vitro and in vivo.Myeloma bone disease: Progress in pathogenesis.Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism.DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.Differential regulation of prostaglandin production mediated by corticotropin-releasing hormone receptor type 1 and type 2 in cultured human placental trophoblasts.Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma.Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo.An ider(17)(q10)t(15;17) with spliced long-type PML-RARA fusion transcripts in a case of acute promyelocytic leukemia.Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cellsRegulation of estradiol and progesterone production by CRH-R1 and -R2 is through divergent signaling pathways in cultured human placental trophoblastsCarfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapyInferior prognosis of gastric involvement in patients with gastrointestinal Burkitt Lymphoma
P50
Q33416468-37C95286-C1D2-4F63-9027-99EB39548619Q33688803-BEA76985-65A2-4679-A02B-0294D599CA24Q35260732-97C0B105-6500-4504-8477-4070C44975FCQ35298727-84F476D5-AE77-4E1B-A0F1-EC7D6D038F4EQ35592352-E5579CBF-C567-49F7-A5A1-B67753E37113Q35932505-0BC2D92B-3F11-48AE-8B3E-CAC6DD54EE28Q36182653-9CE26687-06C0-4877-8479-93629AB5978FQ36413676-B01AF2D5-C543-4415-A994-23EABC79F2FFQ37109841-4FEB0DC8-FA07-4888-BC9D-89299A779C7AQ37301751-E70C8EDF-BAC1-4C71-8856-033A90A7BE3DQ37424884-FB28EBA0-9CDD-472B-A872-053BA34230E6Q37465698-92F7EF02-4DD9-4784-8499-648A464596D2Q38701791-51F9AE6D-D8D2-47D5-926D-2CC61CACABB7Q38734948-2546FAE6-D7D1-4606-987C-353BCFE4A75CQ38836263-775A6E10-AA3D-4AF5-80C6-E0A07A06FE71Q38920028-A34D1C36-DC31-4740-9527-823D346288EAQ38992850-C0993ED7-EE24-4FD8-9AA5-C04101C5FA3CQ45914413-2E0DC680-8D6E-4008-B631-49BD02E857C6Q46714316-655BB963-8507-473C-BAE1-368DC23471F0Q46897494-C2015C87-8DEC-49A9-B24D-99BE34E5EC30Q47107782-63BC0FB2-5ABC-4ACA-BCEC-AF285DD86AC7Q48808585-04209B8B-479F-4A34-8653-4AF899B25A59Q54197886-F5B0FFB1-B583-47D8-8CF7-33969476E1E1Q83582201-9793D688-C93D-49CA-852D-65E3C3009A11Q84734564-A8CBDB68-DA4D-43F4-BE0D-5C4688B38A36Q89237181-95760D56-2162-44CA-BDBA-71F983B54C41Q90238397-5972B6C2-86AE-4F83-A6D5-517A052E13AC
P50
description
researcher ORCID ID=0000-0002-7361-6063
@en
name
Yi Tao
@en
Yi Tao
@nl
type
label
Yi Tao
@en
Yi Tao
@nl
prefLabel
Yi Tao
@en
Yi Tao
@nl
P106
P31
P496
0000-0002-7361-6063